Analysts anticipate Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.31. Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both ...

Vertex Pharmaceuticals (NASDAQ:VRTX) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...

Let's discuss whether Vertex Pharmaceuticals stock is a buy now ... while moving forward with clinical trials in areas like kidney disease and renal disease. Multiple data readouts expected ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals ... trials in areas like kidney disease and renal disease.

BOSTON, April 07, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated ... APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic ...